An Open-label, Multi-center, Long-term Safety Follow-up, Roll-over Study in Patients Who Have Completed a Prior Novartis-sponsored Capmatinib (INC280) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Capmatinib
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 30 Jun 2017 Planned End Date changed from 27 May 2019 to 1 Jul 2019.
- 30 Jun 2017 Planned primary completion date changed from 27 May 2019 to 1 Jul 2019.